Chemotherapy-induced Neutropenia Clinical Trial
Official title:
A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed >/= 1 but < 5 prior lines of chemotherapy; locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with docetaxel (75 mg/m2) + plinabulin (40 mg) versus docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count will be assessed at baseline; Pre dose during Cycle 1, Day 1, 2, 6, 7, 8, 9, 10, 15. *Study is officially closed on 08 Feb 2021*
Arm 1: Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin Arm 2: Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02643901 -
Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT02454530 -
Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study
|
||
| Completed |
NCT02251977 -
Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT02104830 -
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients
|
Phase 3 | |
| Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
| Active, not recruiting |
NCT03294577 -
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
|
Phase 3 | |
| Not yet recruiting |
NCT03701841 -
Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis
|
||
| Completed |
NCT00776165 -
Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)
|
Phase 3 | |
| Completed |
NCT03251768 -
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT04101760 -
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
|
Phase 3 | |
| Completed |
NCT04134429 -
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
|
||
| Completed |
NCT04227990 -
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
|
Phase 2 | |
| Completed |
NCT01569087 -
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients
|
Phase 2 | |
| Completed |
NCT05512676 -
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
|
||
| Completed |
NCT04460079 -
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
|
||
| Recruiting |
NCT02725606 -
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
|
Phase 1 | |
| Completed |
NCT02692742 -
Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
|
Phase 2 | |
| Completed |
NCT02532712 -
Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01516736 -
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
|
Phase 3 | |
| Terminated |
NCT04887831 -
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
|
Phase 2 |